High-stability vitamin B6 injection and preparation method thereof

By adding antioxidants, antidegradants and stabilizers to the vitamin B6 injection, combined with pH adjustment and sterilization treatment, the problem of poor stability of vitamin B6 injection is solved, and high stability under high temperature and strong light conditions are achieved and low content of related substances, meeting the pharmacopoeia standards.

CN118948759AActive Publication Date: 2024-11-15宝利化(南京)制药有限公司

Patent Information

Application Number
CN202411056829.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

Vitamin B6 injection has poor stability during storage and use, especially in high temperature, alkaline environment and strong light conditions, which easily degrade or oxidize, resulting in a decrease in biological activity.

Method used

Using a high-stability vitamin B6 injection formula, each 1000ml contains 100g vitamin B6, 2.5-3.5g antioxidant, 3.6-4.5g antidegradant and 1.2-1.5g stabilizer, sodium bisulfite, sodium metabisulfite, Antioxidants such as sodium thiosulfate and anti-degradable agents such as N-acetylcysteine, and the pH value is adjusted by taurine and megamine as stabilizers, combined with sodium hydroxide, filtered through a 0.22μm filter and 121℃ Sterilization treatment.

Benefits of technology

It significantly improves the stability of vitamin B6 injection, maintains high content and low related substance content, meets the pharmacopoeia standards, and maintains high stability under high temperature and strong light conditions. It still meets the standards after accelerating stability test. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004976688540000061
    Figure BDA0004976688540000061
  • Figure BDA0004976688540000071
    Figure BDA0004976688540000071
  • Figure BDA0004976688540000072
    Figure BDA0004976688540000072
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to a high-stability vitamin B6 injection and a preparation method thereof. Every 1000 ml of the high-stability vitamin B6 injection provided by the invention contains 100 g of vitamin B6, and also contains 2.5 to 3.5 g of an antioxidant, 3.6 to 4.5 g of an anti-degradation agent and 1.2 to 1.5 g of a stabilizer. The antioxidant is one or more of sodium hydrogen sulfite, sodium pyrosulfite and sodium thiosulfate, the anti-degradation agent is N-acetylcysteine, and the stabilizer is taurine and meglumine. The high-stability vitamin B6 injection provided by the invention has high stability, and after 6 months of accelerated stability test, the content of related substances is lower than 0.05% and is far lower than the pharmacopoeia standard.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a high-stability vitamin B6 injection and a preparation method thereof. Background Art

[0002] Vitamin B6, also known as pyridoxine, is a water-soluble vitamin and a member of the vitamin B complex. It plays a key role in many physiological processes of the human body, including amino acid metabolism, nerve conduction and immune function. Vitamin B6 not only participates in the catalysis and regulation of the activity of various enzymes, but also plays an important role in fetal development and erythropoiesis. Modern medical research has found that vitamin B6 deficiency may lead to a series of health problems, including anemia, depression, neuritis, etc. Therefore, vitamin B6 supplementation is widely used in clinical treatment and nutrition and health care.

[0003] However, the properties of vitamin B6 determine many challenges in its storage and use. First, the water solubility of vitamin B6 makes it have different stability under different temperature conditions. Under high temperature or alkaline environment conditions, vitamin B6 will quickly degrade to form inactive metabolites. When stored for a long time or exposed to strong light, vitamin B6 is also prone to oxidation, further reducing its biological activity. Summary of the invention

[0004] In view of this, the purpose of the present invention is to provide a highly stable vitamin B6 injection and a preparation method thereof, so as to solve the problems of short storage time and poor stability of the vitamin B6 injection.

[0005] Based on the above purpose, the present invention provides a highly stable vitamin B6 injection. In addition to containing 100g of vitamin B6, each 1000ml of injection also contains 2.5-3.5g of antioxidant, 3.6-4.5g of antidegradant and 1.2-1.5g of stabilizer.

[0006] Preferably, the antioxidant is one or more of sodium bisulfite, sodium pyrosulfite and sodium thiosulfate.

[0007] Preferably, the antidegradant is N-acetylcysteine.

[0008] Preferably, the stabilizers are taurine and meglumine.

[0009] Preferably, the content of meglumine in the stabilizer is 20wt%-30wt%.

[0010] Preferably, the high-stability vitamin B6 injection has a content of related substances less than 0.05% after 6 months at 40° C. and 75% relative humidity.

[0011] Furthermore, the present invention also provides a method for preparing a highly stable vitamin B6 injection, and the specific preparation steps are as follows:

[0012] (1) Dissolve taurine and meglumine in 200 ml of water for injection at 25-30° C., and adjust the pH with sodium hydroxide;

[0013] (2) Raise the temperature to 40-45°C, add antioxidant and antidegradant, stir to dissolve, and add water for injection to 400 ml;

[0014] (3) Maintaining the temperature at 40-45°C, add vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH with sodium hydroxide;

[0015] (4) Filter through a 0.22 μm filter, fill according to specifications, and then sterilize at 121°C for 15-20 minutes to obtain a highly stable vitamin B6 injection.

[0016] Preferably, in step (1), the pH is adjusted to 6-7.

[0017] Preferably, in step (3), the pH is adjusted to 2.5-3.

[0018] Preferably, the filter membrane material in the filter in step (4) is one of polypropylene and polyethersulfone.

[0019] Preferably, brown medium borosilicate glass ampoules are used for filling in step (4).

[0020] Beneficial effects of the present invention:

[0021] The high-stability vitamin B6 injection provided by the present invention has a high vitamin B6 content and an extremely low content of related substances, meets the pharmacopoeia standards, and after being placed under 65° C. and strong light (6000 lx) conditions for 20 days, it still has a high vitamin B6 content and an extremely low content of related substances. At the same time, after undergoing a 6-month accelerated stability test, it still has a low content of related substances.

[0022] The high-stability vitamin B6 injection provided by the present invention uses taurine and meglumine as stabilizers, and is compounded with antioxidants and anti-degradants, thereby further improving the stability of the vitamin B6 injection. In particular, a trace amount of meglumine can greatly improve the stability of the vitamin B6 injection, which has an unexpected and significant effect.

[0023] The sodium bisulfite and N-acetylcysteine ​​in the present invention can act as sacrificial reducing agents to prevent vitamin B6 from being destroyed during high-temperature sterilization, which is significantly more advanced than the vitamin B6 injection prepared by the traditional formula. DETAILED DESCRIPTION

[0024] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments.

[0025] Embodiment 1:

[0026] (1) Dissolve 0.96 g of taurine and 0.24 g of meglumine in 200 ml of water for injection at 25°C, and adjust the pH to 6.2 with sodium hydroxide;

[0027] (2) Raise the temperature to 40°C, add 2.5 g of sodium bisulfite and 3.6 g of N-acetylcysteine, stir to dissolve, and add water for injection to 400 ml;

[0028] (3) Maintaining the temperature at 40°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.6 with sodium hydroxide;

[0029] (4) Filter through a 0.22 μm polypropylene filter membrane, fill into brown borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 15 minutes to obtain a highly stable vitamin B6 injection.

[0030] Embodiment 2:

[0031] (1) Dissolve 1 g of taurine and 0.35 g of meglumine in 200 ml of water for injection at 25°C, and adjust the pH to 6.4 with sodium hydroxide;

[0032] (2) Raise the temperature to 40°C, add 3g sodium bisulfite and 4g N-acetylcysteine, stir to dissolve, and add water for injection to 400ml;

[0033] (3) Maintaining the temperature at 40°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.8 with sodium hydroxide;

[0034] (4) Filter through a 0.22 μm polypropylene filter membrane, fill into brown medium-borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 18 minutes to obtain a highly stable vitamin B6 injection.

[0035] Embodiment 3:

[0036] (1) Dissolve 1.05 g of taurine and 0.45 g of meglumine in 200 ml of water for injection at 30°C, and adjust the pH to 6.8 with sodium hydroxide;

[0037] (2) Raise the temperature to 45°C, add 3.5 g of sodium bisulfite and 4.5 g of N-acetylcysteine, stir to dissolve, and add water for injection to 400 ml;

[0038] (3) Maintaining the temperature at 45°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.9 with sodium hydroxide;

[0039] (4) Filter through a filter with a 0.22 μm filter membrane of polyethersulfone, fill into brown medium-borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 20 minutes to obtain a highly stable vitamin B6 injection.

[0040] Comparative Example 1:

[0041] (1) Dissolve 3 g of sodium bisulfite and 4 g of N-acetylcysteine ​​in 400 ml of water for injection at 40°C in sequence;

[0042] (2) Maintaining the temperature at 40°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.7 with sodium hydroxide;

[0043] (3) Filter through a 0.22 μm polypropylene filter membrane, fill into brown borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 18 minutes to obtain vitamin B6 injection.

[0044] The difference between Comparative Example 1 and Example 2 is that no stabilizer is added.

[0045] Comparative Example 2:

[0046] (1) Dissolve 1 g of taurine in 200 ml of water for injection at 25°C and adjust the pH to 6.4 with sodium hydroxide;

[0047] (2) Raise the temperature to 40°C, add 3g sodium bisulfite and 4g N-acetylcysteine, stir to dissolve, and add water for injection to 400ml;

[0048] (3) Maintaining the temperature at 40°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.8 with sodium hydroxide;

[0049] (4) Filter through a 0.22 μm polypropylene filter membrane, fill into brown borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 18 minutes to obtain vitamin B6 injection.

[0050] The difference between Comparative Example 2 and Example 2 is that meglumine is not added.

[0051] Comparative Example 3:

[0052] (1) Dissolve 1 g of taurine and 0.35 g of meglumine in 200 ml of water for injection at 25°C, and adjust the pH to 6.4 with sodium hydroxide;

[0053] (2) Raise the temperature to 40°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.8 with sodium hydroxide;

[0054] (3) Filter through a 0.22 μm polypropylene filter membrane, fill into brown borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 18 minutes to obtain vitamin B6 injection.

[0055] The difference between Comparative Example 3 and Example 2 is that sodium bisulfite and N-acetylcysteine ​​are not added.

[0056] Comparative Example 4:

[0057] (1) Dissolve 1 g of taurine and 0.35 g of meglumine in 200 ml of water for injection at 25°C, and adjust the pH to 6.4 with sodium hydroxide;

[0058] (2) Raise the temperature to 40°C, add 3 g of sodium bisulfite, stir to dissolve, and add water for injection to 400 ml;

[0059] (3) Maintaining the temperature at 40°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.8 with sodium hydroxide;

[0060] (4) Filter through a 0.22 μm polypropylene filter membrane, fill into brown borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 18 minutes to obtain vitamin B6 injection.

[0061] The difference between Comparative Example 4 and Example 2 is that N-acetylcysteine ​​is not added.

[0062] Comparative Example 5:

[0063] (1) Dissolve 1 g of taurine and 0.35 g of meglumine in 200 ml of water for injection at 25°C, and adjust the pH to 6.4 with sodium hydroxide;

[0064] (2) Raise the temperature to 40°C, add 4 g of N-acetylcysteine, stir to dissolve, and add water for injection to 400 ml;

[0065] (3) Maintaining the temperature at 40°C, add 100 g of vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH to 2.8 with sodium hydroxide;

[0066] (4) Filter through a 0.22 μm polypropylene filter membrane, fill into brown borosilicate glass ampoules according to specifications, and then sterilize at 121°C for 18 minutes to obtain vitamin B6 injection;

[0067] The difference between Comparative Example 5 and Example 2 is that no sodium bisulfite is added.

[0068] For ease of understanding, the experimental data of the embodiments and comparative examples are presented in Table 1, as shown below.

[0069] Table 1 Experimental data table

[0070]

[0071]

[0072] As can be seen from Examples 1-3 in Table 1, the vitamin B6 injection obtained by using the prescription provided by the present invention has a high content and extremely low content of related substances, which meets the pharmacopoeia standards;

[0073] It can be seen from Comparative Examples 1-5 in Table 1 that sodium bisulfite and N-acetylcysteine ​​help to reduce the content of related substances in vitamin B6 injection, which is mainly because sodium bisulfite and N-acetylcysteine ​​can act as sacrificial reducing agents to prevent vitamin B6 from being destroyed during high-temperature sterilization, and the combination of taurine and meglumine also helps to further reduce the content of related substances in vitamin B6 injection.

[0074] The samples prepared in the examples and comparative examples were subjected to an influencing factor test and placed under 65° C. and strong light (6000 lx) conditions for 20 days to examine the stability of the samples. The results are shown in Table 2.

[0075] Table 2 High temperature and strong light test results

[0076]

[0077] It can be seen from the data of Examples 1-3 in Table 2 that the high-stability vitamin B6 injection provided by the present invention still has a high vitamin B6 content and an extremely low content of related substances after being placed under 65° C. and strong light (6000 lx) conditions for 20 days, indicating that it has excellent stability under high temperature and strong light.

[0078] It can be seen from the data of Example 2 and Comparative Examples 1-5 in Table 2 that sodium bisulfite and N-acetylcysteine ​​are essential for maintaining the stability of vitamin B6 injection under high temperature and strong light, and taurine and meglumine can further improve the stability, especially a small amount of meglumine can greatly improve the stability of vitamin B6 injection, which has an unexpected significant effect.

[0079] The samples prepared in the examples and comparative examples were subjected to an accelerated stability test, and were placed at a temperature of 40° C. and a relative humidity of 75% for 6 months to examine the stability of the samples. The results are shown in Table 3.

[0080] Table 3 Accelerated stability test results

[0081]

[0082] It can be seen from the data of Examples 1-3 in Table 3 that after 6 months of accelerated testing, the vitamin B6 injection provided by the present invention still has a low content of related substances and excellent stability. It can be seen from the data of Comparative Examples 1-5 that they all show varying degrees of degradation, and the content of related substances far exceeds the pharmacopoeia standards, indicating that the vitamin B6 injection prepared by the formula provided by the present invention is significantly advanced compared to the vitamin B6 injection prepared by the traditional formula.

[0083] Those skilled in the art should understand that the discussion of any of the above embodiments is merely illustrative and is not intended to imply that the scope of the present invention is limited to these examples. Under the concept of the present invention, the technical features in the above embodiments or different embodiments may be combined, the steps may be implemented in any order, and there are many other variations of the different aspects of the present invention as described above, which are not provided in detail for the sake of simplicity.

Claims

1. A highly stable vitamin B6 injection, It is characterized in that In addition to 100g of vitamin B6, each 1000ml of injection solution also contains 2.5-3.5g of antioxidants, 3.6-4.5g of anti-degradants and 1.2-1.5g of stabilizers.

2. The highly stable vitamin B6 injection according to claim 1, It is characterized in that The antioxidant is one or more of sodium bisulfite, sodium pyrosulfite and sodium thiosulfate.

3. The highly stable vitamin B6 injection according to claim 1, It is characterized in that The antidegradant is N-acetylcysteine.

4. The highly stable vitamin B6 injection according to claim 1, It is characterized in that The stabilizer is taurine and meglumine; the content of meglumine in the stabilizer is 20wt%-30wt%.

5. The highly stable vitamin B6 injection according to claim 1, It is characterized in that The high-stability vitamin B6 injection has a content of related substances lower than 0.05% after being placed at 40° C. and 75% relative humidity for 6 months.

6. A method for preparing the highly stable vitamin B6 injection according to claims 1-5, It is characterized in that The specific preparation steps are as follows: (1) Dissolve taurine and meglumine in 200 ml of water for injection at 25-30° C., and adjust the pH with sodium hydroxide; (2) Raise the temperature to 40-45°C, add antioxidant and antidegradant, stir to dissolve, and add water for injection to 400 ml; (3) Maintaining the temperature at 40-45°C, add vitamin B6, stir to dissolve, add water for injection to 1000 ml and adjust the pH with sodium hydroxide; (4) Filter through a 0.22 μm filter, fill according to specifications, and then sterilize at 121°C for 15-20 minutes to obtain a highly stable vitamin B6 injection.

7. The method for preparing the highly stable vitamin B6 injection according to claim 6, It is characterized in that In the step (1), the pH is adjusted to 6-7.

8. The method for preparing the highly stable vitamin B6 injection according to claim 6, It is characterized in that In step (3), the pH is adjusted to 2.5-3.

9. The method for preparing the highly stable vitamin B6 injection according to claim 6, It is characterized in that The filter membrane material in the filter in step (4) is one of polypropylene and polyethersulfone.

10. The method for preparing the highly stable vitamin B6 injection according to claim 6, It is characterized in that In the step (4), brown medium borosilicate glass ampoules are used for filling.

Citation Information

Patent Citations

  • Modified injection containing 13 compound vitamins and preparation method thereof

    CN102652744A

  • Magnetic sodium cantharidinate vitamin B6 compound preparation and preparation method thereof

    CN104814959A

  • Vitamin-containing nutrition infusion for administration through peripheral vein

    CN106924181A

  • Vitamin B6 injection and preparation method thereof

    CN118403008A

  • Injection contg. seven vitamins and taurine

    CN1911220A

Cited By

  • High-stability vitamin B6 injection

    CN122499105A